ORPHA:99977
Squamous cell carcinoma of the esophagus
Also known as: ESCC · Esophageal epidermoid carcinoma · Esophageal squamous cell carcinoma
Publications
54,733
99.3th percentile
Trials
569
Interventional, condition-specific
Researchers
1,131
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Esophageal squamous cell carcinoma (ESCC) is a type of esophageal carcinoma (EC) that can affect any part of the esophagus, but is usually located in the upper or middle third.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005580
- MeSH:C562729
- MeSH:D000077277
- UMLS:C0279626
- NCIT:C4024
Additional Mondo synonyms (16)
esophageal epidermoid carcinoma · esophageal scc · esophageal squamous cell cancer · esophageal squamous cell carcinoma · esophagus scc · esophagus squamous cell carcinoma · oesophagus scc · scc of esophagus · scc of the esophagus · scc of the oesophagus · squamous cell car. - esophagus · squamous cell car. - oesophagus · squamous cell carcinoma of esophagus · squamous cell carcinoma of oesophagus · squamous cell carcinoma of the esophagus · squamous cell carcinoma of the oesophagus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
54,733 matched papers (40,244 in last 10 years) Source
- Phenotype characterisedPresent
8 HPO annotations (e.g. Clinodactyly of the 5th toe; Nausea and vomiting; Lymphadenopathy) Source
- Animal modelPresent
1 genotype model (Rattus norvegicus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
569 matched on ClinicalTrials.gov (211 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
8
Associated phenotypes · MONDO:0005580
- Clinodactyly of the 5th toe
- Nausea and vomiting
- Lymphadenopathy
- Feeding difficulties in infancy
- Esophageal carcinoma
Showing 5 of 8 — open Monarch for the full list.
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- SD-Mir31em1Sage·RGD:127285380·Rattus norvegicus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
144
Drugs / clinical candidates · MONDO_0005580
- ATEZOLIZUMAB·phase 3
- BENMELSTOBART·phase 3
- CAFFEIC ACID·phase 3
- CAMRELIZUMAB·phase 3
- CAPECITABINE·phase 3
- CARBOPLATIN·phase 3
- CATEQUENTINIB HYDROCHLORIDE·phase 3
- CISPLATIN·phase 3
- DOCETAXEL·phase 3
- DURVALUMAB·phase 3
- FLUOROURACIL·phase 3
- GIMERACIL·phase 3
- IFINATAMAB DERUXTECAN·phase 3
- IPILIMUMAB·phase 3
- IRINOTECAN·phase 3
CTD chemicals (MyDisease.info)
17 associated chemicals · 764 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- CF regimen · therapeutic
- Cisplatin · therapeutic
- Cysteine Proteinase Inhibitors · therapeutic
- diallyl trisulfide · therapeutic
- Docetaxel · therapeutic
- Fluorouracil · therapeutic
- isoalantolactone · therapeutic
- longikaurin A · therapeutic
- Mitomycin · therapeutic
- Vindesine · therapeutic
- Vinorelbine · therapeutic
- Zinc · therapeutic
Pathways: Glycolysis / Gluconeogenesis; Fructose and mannose metabolism; Ascorbate and aldarate metabolism; Fatty acid biosynthesis; Fatty acid degradation; Caffeine metabolism; Pyrimidine metabolism; Valine, leucine and isoleucine degradation
Literature
Is anyone studying this?
54,733
54,733 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
54,733 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
40,244 in the last 10 years · medium confidence · 99.3th percentile (publications denominator)
Phrase hits: 54,733 · MeSH hits: 889
Who's working on it?
1,131
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y17 papers · 2026
Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Papers in Europe PMC - 02Li Y14 papers · 2026
Department of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Guangwen Street, NO.151, Weifang City, Shandong Province, China.
Papers in Europe PMC - 03Li J13 papers · 2026
Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
Papers in Europe PMC - 04Zhang Y10 papers · 2026
Department of Thoracic Surgery, Quanzhou First Hospital, Fujian, 362000, China.
Papers in Europe PMC - 05Li Z9 papers · 2026
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 06Zhang H9 papers · 2026
Department of Thoracic Surgery, Shandong Public Health Clinical Center, Shandong University, Public Health Clinical Center Affiliated to Shandong University, Jinan, PR China.
Papers in Europe PMC - 07Zhang J9 papers · 2026
Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiaxing University, Jiaxing, Zhejiang Province.
Papers in Europe PMC - 08Zhang X9 papers · 2026
Engineering Research Center of Immunocellular Therapy, Beijing, China.
Papers in Europe PMC - 09Li S8 papers · 2026
Department of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Guangwen Street, NO.151, Weifang City, Shandong Province, China.
Papers in Europe PMC - 10Liu Z8 papers · 2026
Department of Radiation Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China; Department of Radiation Oncology, Hunan Cancer Hospital, Changsha, Hunan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
569
interventional trials for this specific condition
569 interventional trials matched this specific condition name; 211 currently recruiting in our sample. 2,012 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
569 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.7th percentile).
medium confidence · 99.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
569 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07403435·NOT YET RECRUITING·Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT05208762·RECRUITING·A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Not reviewed·Conditions: Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of the Head and Neck · Esophageal Squamous Cell Carcinoma · Triple Negative Breast Neoplasms·Matched via name + MeSH
- NCT07317609·RECRUITING·Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT07627347·RECRUITING·Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
Not reviewed·Conditions: ESCC·Matched via name + MeSH
- NCT07263919·RECRUITING·Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Not reviewed·Conditions: Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT05919030·RECRUITING·A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT06602843·RECRUITING·Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT07359417·RECRUITING·MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Cancer, Squamous Cell·Matched via name + MeSH
- NCT06681285·NOT YET RECRUITING·Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
Not reviewed·Conditions: Esophageal Carcinoma·Matched via name + MeSH
- NCT07622797·RECRUITING·Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Late-stage Resectable Esophageal Squamous Carcinoma·Matched via name + MeSH
- NCT06535607·RECRUITING·Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Not reviewed·Conditions: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) · Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)·Matched via name + MeSH
- NCT05473156·RECRUITING·A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Not reviewed·Conditions: Locally Advanced or Metastatic Solid Tumors · Non Small Cell Lung Cancer (NSCLC) · Head and Neck Squamous Cell Carcinoma (HNSCC) · Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT04138212·RECRUITING·Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT07618910·NOT YET RECRUITING·Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT07277413·RECRUITING·A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Not reviewed·Conditions: NSCLC Adenocarcinoma · Gastroesophageal Cancer (GC) · Gastric Adenocarcinoma · Adenocarcinoma of Esophagus·Matched via name phrase
Broader category: squamous cell carcinoma
2,012
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
- NCT06492460·RECRUITING·2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck·Matched via name phrase
- NCT07337161·RECRUITING·Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
Not reviewed·Conditions: Cutaneous · Head and Neck Cancer Squamous Cell Carcinoma·Matched via name phrase
- NCT05172245·RECRUITING·Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary · Locally Advanced Head and Neck Squamous Cell Carcinoma·Matched via name phrase
Observational and natural-history studies
88 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07224750·RECRUITING·A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Not reviewed·Conditions: Hepatocellular Carcinoma (HCC) · Cholangiocarcinoma · Pancreatic Ductal Adenocarcinoma (PDAC) · Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT07152535·NOT YET RECRUITING·Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT05759325·NOT YET RECRUITING·An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Squamous Cell Carcinoma of Esophagus·Matched via name + MeSH
- NCT07697898·NOT YET RECRUITING·TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT07353541·NOT YET RECRUITING·Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Fistula·Matched via name + MeSH
- NCT06561178·RECRUITING·Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT05392413·RECRUITING·Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma · PD-1 Inhibitor·Matched via name + MeSH
- NCT05894369·RECRUITING·Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Cancer·Matched via name + MeSH
- NCT07567716·ENROLLING BY INVITATION·Infiltration Pattern of Locally Advanced ESCC
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC) · Infiltration · Tumour·Matched via name + MeSH
- NCT07080437·RECRUITING·An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name + MeSH
- NCT07533357·NOT YET RECRUITING·Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Cancer·Matched via name + MeSH
- NCT07088354·RECRUITING·Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma · Neoadjuvant Immunochemotherapy · Pathological Complete Response · Deep Learning·Matched via name + MeSH
- NCT06408584·RECRUITING·Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name + MeSH
- NCT05740995·RECRUITING·Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma · Neoadjuvant Chemoimmunotherapy·Matched via name + MeSH
- NCT05833594·RECRUITING·Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma · Chemoradiotherapy · Immunonutrition · Inoperable·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- ctis·2024-518358-17-00·Authorised, ongoing·SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal squamous-cell carcinoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-511403-41-00·Cancelled·A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
skipped — LLM skipped (--skip-llm)
- ctis·2023-503312-32-00·Expired·TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91431511·No longer recruiting·Does screening with the Galleri test in the NHS reduce the likelihood of a late-stage cancer diagnosis?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10570964·No longer recruiting·Observational study to evaluate PD-L1 protein expression in Chinese patients with advanced esophageal cancers and head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54829649·No longer recruiting·Chemotherapy Followed by Surgery versus Surgery Alone in Patients with Oesophageal Squamous Cell Carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80832026·No longer recruiting·Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinomas or squamous cell carcinomas of the esophagus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45750457·No longer recruiting·Accuracy of FDG-PET and spiral CT for the early prediction of non-response to preoperative chemoradiotherapy in patients with oesophageal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the esophagus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the esophagus" OR "Squamous cell carcinoma of esophagus" OR "Esophageal epidermoid carcinoma" OR "Esophageal squamous cell carcinoma" OR "esophageal scc" OR "esophageal squamous cell cancer" OR "esophagus scc" OR "esophagus squamous cell carcinoma" OR "oesophagus scc" OR "scc of esophagus" OR "scc of the esophagus" OR "scc of the oesophagus" OR "scc of oesophagus" OR "squamous cell car. - esophagus" OR "squamous cell car. - oesophagus" OR "squamous cell carcinoma of oesophagus" OR "squamous cell carcinoma of the oesophagus"
MeSH descriptor terms unioned into the query: [OBSOLETE] Esophageal Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the esophagus" OR "Squamous cell carcinoma of esophagus" OR "Esophageal epidermoid carcinoma" OR "Esophageal squamous cell carcinoma" OR "esophageal scc" OR "esophageal squamous cell cancer" OR "esophagus scc" OR "esophagus squamous cell carcinoma" OR "oesophagus scc" OR "scc of esophagus" OR "scc of the esophagus" OR "scc of the oesophagus" OR "scc of oesophagus" OR "squamous cell car. - esophagus" OR "squamous cell car. - oesophagus" OR "squamous cell carcinoma of oesophagus" OR "squamous cell carcinoma of the oesophagus" OR "[OBSOLETE] Esophageal Squamous Cell Carcinoma"
Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 569 interventional · 88 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ESCC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T06:50:14.572Z
